glp 1 reviews and complaints GLP-1 agonists changes in body mass and composition in adults with overweight or obesity with or without type 2 diabetes mellitus: a systematic review and meta-analysis A new review by Clifford
Description
Beyond clinical efficacy, the company that secures uninterrupted global supply and manufacturing scale could dominate the market
It is clinically significant
Reduced caloric intake combined with new metabolic signaling can affect energy availability, recovery capacity, and blood sugar stability during intense workouts
Most troubling is a finding that health plans, such as UnitedHealthcare, noted a 10% year-over-year increase in emergency department visits among members initiating GLP-1 therapies
10.1001/jama.2024.10333
